Authors: Szabo, Peter A.; Dogra, Pranay; Gray, Joshua I.; Wells, Steven B.; Connors, Thomas J.; Weisberg, Stuart P.; Krupska, Izabela; Matsumoto, Rei; Poon, Maya M.L.; Idzikowski, Emma; Morris, Sinead E.; Pasin, Chloé; Yates, Andrew J.; Ku, Amy; Chait, Michael; Davis-Porada, Julia; Guo, Xinzheng V.; Zhou, Jing; Steinle, Matthew; Mackay, Sean; Saqi, Anjali; Baldwin, Matthew R.; Sims, Peter A.; Farber, Donna L.
Online: https://linkinghub.elsevier.com/retrieve/pii/S1074761321001175
Issue: Immunity . 2021 Apr 13;54(4):797-814.e6.
Abstract
Immune response dynamics in coronavirus disease 2019 (COVID-19) and their severe manifestations have largely been studied in circulation. Here, we examined the relationship between immune processes in the respiratory tract and circulation through longitudinal phenotypic, transcriptomic, and cytokine profiling of paired airway and blood samples from patients with severe COVID-19 relative to heathy controls. In COVID-19 airways, T cells exhibited activated, tissue-resident, and protective profiles; higher T cell frequencies correlated with survival and younger age. Myeloid cells in COVID-19 airways featured hyperinflammatory signatures, and higher frequencies of these cells correlated with mortality and older age. In COVID-19 blood, aberrant CD163+ monocytes predominated over conventional monocytes, and were found in corresponding airway samples and in damaged alveoli. High levels of myeloid chemoattractants in airways suggest recruitment of these cells through a CCL2-CCR2 chemokine axis. Our findings provide insights into immune processes driving COVID-19 lung pathology with therapeutic implications for targeting inflammation in the respiratory tract.
